Anzeige
Mehr »
Samstag, 30.08.2025 - Börsentäglich über 12.000 News
Megatrend Uran: Die Nachfrage nach Uran explodiert - greift jetzt Buffetts Erfolgsrezept?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40YEP | ISIN: CA03835T4081 | Ticker-Symbol: LTI0
Frankfurt
29.08.25 | 08:02
1,030 Euro
+6,19 % +0,060
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
APTOSE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
APTOSE BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0101,16029.08.
1,0501,12029.08.

Aktuelle News zur APTOSE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
APTOSE BIOSCIENCES Aktie jetzt für 0€ handeln
22.08.Aptose Biosciences Inc (4): Aptose Biosciences appoints Ernst & Young auditor2
22.08.Aptose Biosciences, Inc.: Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor122SAN DIEGO and TORONTO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib...
► Artikel lesen
22.08.Aptose Biosciences Inc. - 8-K, Current Report1
18.08.Aptose Biosciences Inc (4): Aptose releases Tuspetinib early results for AML1
18.08.Aptose Biosciences, Inc.: Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial114Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AMLAddition of TUS to VEN+AZA improves response rates...
► Artikel lesen
13.08.Aptose Biosciences Inc. - 8-K, Current Report3
13.08.Aptose Biosciences Inc. - 10-Q, Quarterly Report1
13.08.Aptose Biosciences, Inc.: Aptose Reports Second Quarter 2025 Results71Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at 120 mg Dose Cohort Safety Review...
► Artikel lesen
06.08.Aptose Biosciences Inc. - 8-K, Current Report1
06.08.Aptose Biosciences, Inc.: Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy56Safety Review Committee endorses escalation to 160 mg TUS dosingCohorts with 120 mg, 80 mg, 40 mg TUS dosing completed with no dose-limiting toxicities Excellent safety and complete remissions (CRs)...
► Artikel lesen
01.08.Aptose Biosciences Inc (4): Aptose Biosciences selects Ernst & Young as auditor1
01.08.Aptose Biosciences, Inc.: Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders2
21.07.NSE - Aptose Biosciences Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities3
16.07.Aptose Biosciences Inc (4): Aptose receives advance of $2M (U.S.) from facility3
15.07.Aptose Biosciences, Inc.: Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML166SAN DIEGO and TORONTO, July 15, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib...
► Artikel lesen
15.07.Aptose Biosciences Inc. - 8-K, Current Report1
01.07.Aptose Biosciences, Inc.: Aptose Upgraded to Trade on OTCQB Market186SAN DIEGO and TORONTO, July 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib...
► Artikel lesen
01.07.Aptose Biosciences Inc. - 8-K, Current Report1
01.07.Aptose Biosciences Inc (4): Aptose Biosciences, Hanmi enter interest deferral deal2
30.06.Aptose Biosciences, Inc.: Aptose Announces Deferral of Interest Payment3
Weiter >>
77 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1